Elixir Medical Announces Excellent Results from DESolve I First-In-Man Study for the Fully Bioresorbable Drug Eluting Coronary Scaffold System  
5/16/2012 10:54:53 AM

SUNNYVALE, Calif. & PARIS--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, today announced outstanding six-month clinical, IVUS (Intravascular Ultrasound), OCT (Optical Coherence Tomography), and angiographic data for its 15-patient First-In-Man clinical study of the fully bioresorbable drug-eluting scaffold, the DESolveā„¢ Bioresorbable Coronary Scaffold System at a late-breaking trial session of EuroPCR in Paris.